Form 4: Corcept Therapeutics Director James N. Wilson Reports Share Transfer

Director James N. Wilson reported a transfer of 7,800 common shares to a trust, maintaining indirect beneficial ownership.

Summary

• James N. Wilson, a director at Corcept Therapeutics, reported a transaction involving the transfer of 7,800 common shares.
• The shares were transferred on December 27, 2024.
• The transfer was a disposition of shares at a price of $0.
• Following the transaction, Mr. Wilson indirectly beneficially owns 1,306,226 shares through the James N. Wilson and Pamela D. Wilson Trust and 901,067 shares through James and Pamela Wilson Family Partners.
• Mr. Wilson disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and there is no indication of positive or negative sentiment.

Management Comments

• Mr. Wilson disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company director, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for company insiders, such as directors, to report changes in their beneficial ownership of company stock.
• The reporting requirements are consistent across all publicly traded companies in the US, ensuring transparency and compliance with SEC regulations.
• The transaction is a transfer of shares, not a sale, which is a common type of transaction reported in Form 4 filings.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it is a transfer of shares and not a sale.

Key Dates

Keywords

Corcept Therapeutics, James N. Wilson, share transfer, beneficial ownership, director, CORT, SEC Form 4